These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 36977465)
1. Cell-Based Biomaterials for Coronavirus Disease 2019 Prevention and Therapy. Li C; Wang C; Xie HY; Huang L Adv Healthc Mater; 2023 Jul; 12(18):e2300404. PubMed ID: 36977465 [TBL] [Abstract][Full Text] [Related]
2. [Applications of separation technology in novel coronavirus research, epidemic prevention and detection]. Li L; Zhu C; Zhao X; Qu F Se Pu; 2021 Jul; 39(7):679-685. PubMed ID: 34227364 [TBL] [Abstract][Full Text] [Related]
3. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development. Begum J; Mir NA; Dev K; Buyamayum B; Wani MY; Raza M Transbound Emerg Dis; 2021 May; 68(3):1111-1124. PubMed ID: 32815655 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive analyses of bioinformatics applications in the fight against COVID-19 pandemic. Ma L; Li H; Lan J; Hao X; Liu H; Wang X; Huang Y Comput Biol Chem; 2021 Dec; 95():107599. PubMed ID: 34773807 [TBL] [Abstract][Full Text] [Related]
5. Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2. Mufamadi MS; Ngoepe MP; Nobela O; Maluleke N; Phorah B; Methula B; Maseko T; Masebe DI; Mufhandu HT; Katata-Seru LM Biomed Res Int; 2023; 2023():4588659. PubMed ID: 37181817 [TBL] [Abstract][Full Text] [Related]
6. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related]
7. Pathogenesis-directed therapy of 2019 novel coronavirus disease. Stratton CW; Tang YW; Lu H J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355 [TBL] [Abstract][Full Text] [Related]
8. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
9. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future]. Ye ZW; Jin DY Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053 [TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy. Mirtaleb MS; Mirtaleb AH; Nosrati H; Heshmatnia J; Falak R; Zolfaghari Emameh R Biomed Pharmacother; 2021 Jun; 138():111518. PubMed ID: 33774315 [TBL] [Abstract][Full Text] [Related]
11. Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19. Mustajab T; Kwamboka MS; Choi DA; Kang DW; Kim J; Han KR; Han Y; Lee S; Song D; Chwae YJ Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232549 [TBL] [Abstract][Full Text] [Related]
12. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096 [TBL] [Abstract][Full Text] [Related]
13. Human and novel coronavirus infections in children: a review. Rajapakse N; Dixit D Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199 [TBL] [Abstract][Full Text] [Related]
14. Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic. Liu CH; Huang HY; Tu YF; Lai WY; Wang CL; Sun JR; Chien Y; Lin TW; Lin YY; Chien CS; Huang CH; Chen YM; Huang PI; Wang FD; Yang YP J Chin Med Assoc; 2021 Jan; 84(1):9-13. PubMed ID: 33186212 [TBL] [Abstract][Full Text] [Related]
15. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278 [TBL] [Abstract][Full Text] [Related]
16. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. Abdurrahman L; Fang X; Zhang Y Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374 [TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
18. An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19. Ghaffari S; Kazerooni H; Salehi-Najafabadi A Int Immunopharmacol; 2021 Dec; 101(Pt B):108226. PubMed ID: 34634685 [TBL] [Abstract][Full Text] [Related]
19. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172 [TBL] [Abstract][Full Text] [Related]
20. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]